Pharmaceutical Technology on MSN7d
Augustine secures $85m to advance Charcot-Marie-Tooth candidate
AGT-100216 will now enter a Phase I/II proof-of-concept clinical trial for CMT disease, with patient enrolment set to begin ...
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the ...
pharmaphorum7d
Augustine decloaks with $85m for nerve disease programme
Augustine Therapeutics has raised €78 million ($85 million) in first-round funding for a pipeline headed by a candidate for ...
BioPharma Dive5d
Bayer gains cancer drug from China’s Puhe; Axsome gets mixed ADHD data
The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...
Jeito Capital Co-Leads €78 Million Financing in Augustine Therapeutics
By Karen Roman Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) ...
Morningstar7d
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round
Augustine Therapeutics have designed a unique next-generation approach to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. This novel non-hydroxamate, non ...